Send to:

Choose Destination
See comment in PubMed Commons below
Semin Oncol. 2006 Feb;33(1 Suppl 3):S33-6.

Future perspectives in the treatment of cutaneous T-cell lymphoma (CTCL).

Author information

  • 1Department of Dermatology, University Hospital of Zurich, Switzerland.


Over the last 20 years the treatment of cutaneous T-cell lymphoma has been in a state of continual change. New therapies are constantly emerging as the search continues for more effective and tolerable disease-specific agents that satisfy medical needs. Therapies under investigation include topical retinoids, fusion molecules like denileukin diftitox, pegylated interferon, interleukin-2, and interleukin-12. Pegylated liposomal doxorubicin, gemcitabine, and chlorodeoxyadenosine also appear to have clinical potential. Other identified agents include vaccines and monoclonal antibodies. This article reviews some of the most recent clinical innovations.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk